EP0111529A1 - Arzneimittel zur behandlung der neoplasikkrankheit - Google Patents
Arzneimittel zur behandlung der neoplasikkrankheitInfo
- Publication number
- EP0111529A1 EP0111529A1 EP83901948A EP83901948A EP0111529A1 EP 0111529 A1 EP0111529 A1 EP 0111529A1 EP 83901948 A EP83901948 A EP 83901948A EP 83901948 A EP83901948 A EP 83901948A EP 0111529 A1 EP0111529 A1 EP 0111529A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- solution
- herba
- ratio
- case
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title claims abstract description 9
- 201000010099 disease Diseases 0.000 title claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 7
- 239000002775 capsule Substances 0.000 claims abstract description 18
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940098465 tincture Drugs 0.000 claims abstract description 10
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 5
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims abstract description 5
- 229910052939 potassium sulfate Inorganic materials 0.000 claims abstract description 5
- 239000001120 potassium sulphate Substances 0.000 claims abstract description 5
- 235000011151 potassium sulphates Nutrition 0.000 claims abstract description 5
- 229910002007 uranyl nitrate Inorganic materials 0.000 claims abstract description 5
- 241000693827 Helleborus niger Species 0.000 claims abstract description 4
- 241000581692 Potentilla reptans Species 0.000 claims abstract description 4
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960000907 methylthioninium chloride Drugs 0.000 claims abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 3
- 241000534456 Arenaria <Aves> Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000003387 muscular Effects 0.000 claims description 2
- 235000012745 brilliant blue FCF Nutrition 0.000 claims 1
- 238000001802 infusion Methods 0.000 abstract description 10
- 240000004658 Medicago sativa Species 0.000 abstract description 3
- 235000010624 Medicago sativa Nutrition 0.000 abstract description 3
- 241000218176 Corydalis Species 0.000 abstract description 2
- ZVNPWFOVUDMGRP-UHFFFAOYSA-N 4-methylaminophenol sulfate Chemical compound OS(O)(=O)=O.CNC1=CC=C(O)C=C1.CNC1=CC=C(O)C=C1 ZVNPWFOVUDMGRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 235000013311 vegetables Nutrition 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- OVBPIULPVIDEAO-GFCCVEGCSA-N (2r)-2-[[4-[(2-amino-4-oxo-1h-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-GFCCVEGCSA-N 0.000 description 1
- LPJXPACOXRZCCP-VIFPVBQESA-N (2s)-2-benzamidopentanedioic acid Chemical class OC(=O)CC[C@@H](C(O)=O)NC(=O)C1=CC=CC=C1 LPJXPACOXRZCCP-VIFPVBQESA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 230000003098 cholesteric effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- JOSBTZULDGZZRE-UHFFFAOYSA-N elanine Natural products CCC(C)C(=O)OC1C2CC3C1C(O)(CC2OC)C4(O)C(OC)C5C6(COC(=O)c7ccccc7N8C(=O)CC(C)C8=O)CCC(OC)C35C4N(CC)C6 JOSBTZULDGZZRE-UHFFFAOYSA-N 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- -1 potash ion Chemical class 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 235000011127 sodium aluminium sulphate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/50—Fumariaceae (Fumitory family), e.g. bleeding heart
- A61K36/505—Corydalis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- This invention refers to a meicin used for the tratment of socie neoplazic diseases, for acute leukemia, for the Hodgkin disease, for the Eahler disease and for the thrombocytopenic purple.
- the main groups of thia type of medicines are the hormones, the alkylation agents as for instance isoyparites, ethyleniminss, esther of the methanolsulphonic acid and antimetabolic agents as the antagoniste of the folie acid, of purine and pyrimidins and of emino-acids.
- aminoglutamic and benzoyl glutamic acids a.s.o aminoglutamic and benzoyl glutamic acids a.s.o
- various nctural products colchicina and vincristina
- the medicine broadens the series of therapeutic products used in the thepapy of the neoplazic cisease, the highly efficient medicine conoisting of a set of three drug types in which hydroquinone and motolo with or without double aluminum and potassium sulphate are mixed at a ratio of 50: 1 in operculated capsules, the uranyl nitrate being dissolved at a ratio of 1g to 100 g solution of Cordalis merchaliana infusion which contains 0.01 ml.
- a 40% alcoholic vegetal tincture is used as a treatment aid being obtained from Herba Potentilla reptans, Eadix Helleborus niger and Herba Medicago sativa according to the association ratio of the alcbholate of dry plants of 10: 3: 3, in the case of the eolostasis hepatitis it is associated with a decoction, of Herba Helicrisium arenaria.
- the medicine has the following advantages.
- - may be used in the postsurgieal therapy.
- the medicine is presented as a set of three drug types as follows: a) Operculated capsules containing 0.5g hydroquinone and O.ol g metole (C 17 ) or operculated capsules containing 0.5g hydroquinone, 0.01g metole and O.o2 double aluminum and potassium sulphate. b) Uranyl nitrate 1% solution of aoueous infusion of Coridalis marchaliana, infusion which contains 0.010 ml. 1% solution of methylene blue (UFO 8 solution).
- the operculoted capsules containing a C 17 or V composition are prepared according to the ordinary phar maceutical technology.
- Corydalis marchaliana infusion is obtained of 0.200 g of dry plant in 100 ml. Of water, and in this cold infusion 1% mrthylrne blue id added, and the uranyl nitrate is dissolved.
- the Hbp vegetal tincture is obtained by the maceration of the chopped dry plants, at the above ratios, in one liter of ethylic alcohol 40%, for 20 days. After the maceration, the supernatant liquid is decanted thus contituting the Hbp vegetal tincture.
- one C 17 or V capsule is taken daily with an infusion of Coride lis marchaliana, (25 ml.pt least), and, in the case of the tumors or musculcr tissue with another 5 ml.of Hbp alcoholic vegetal tincture diluted in 25 ml. of water or Coridalis infusion, 2-3 times a day for 1-6 months after which 1 drop of UFO 8 solution per 10 kg. of body is recomended for 1-2 months also associated with the Hbp alcoholic vegetal tincture.
- the total cure is of 6-10 months.
- the C 1 7 or V capsules will be taken intermittently once in two days.
- the treatment necessarily lests 6 months- 1 year.
- the V operculsted capsules are highly efficient.
- the presence of tho potash alum and sodium alum is necescary because the potash ion represents an exogenio contribution to the prostetic group of the mitochondrial enzymes.
- the V operculated capsules also are recomeended for the treatment of the aggressive ehronic hepatitis intermittently, once in two days.
- the Herba Helicrisium arenarium decoction is recommended at a ratio of 0.5g-1g dry plant in 250 ml. of water, as a treatment aid with cholesteric and cholagogic effects which is taken in the morning, before brenkfast, periodically for seven days.
- V operculated capsules For the treatment of miastenia gravis the highly efficient V operculated capsules are recommended, in which the double aluminum and potassium sulphate is of 0.04 g for an operculated capsule daily, the cure consisting in one capsule daily.
- the C 17 operculated capsules and the UFO 8 solution will be administered in alternating cures of 4-5 months, both of them per os. The same treatment is recommended for the lungs cancer.
- the UFO 8 solution will be administered per os, 1 drop per 10 kg. of body, in 50 ml of water or Coridalis infusion, in the monrning, before breakfast.
- the rhythm of the cure is of 5 days with a break of two days, for 5-6 months.
- the U FO 8 solution may be used in local applications, as an intrapleural and intraperitoneal treatment in the case of the corcinomatous pleuresy and peritonitis, determining a quick resorption of the carcinomotous liquid.
- the UFO 8 solution will be sterili zed after a dilution with distilled water at a ratio of 1: 5.
- the diseased will take C 17 operculated capsules per os, one capsule daily.
- the daily local application of the UFO 8 solution or the daily ocular instillations for 1-2 months proved to be very efficient.
- the Hbp vegetal tincture together with the other drugs in the composition of the medicine have, according to the invetion, an immunologie influence on the organism.
- an immunologie influence on the organism in the case of chronic obstructive bronchopathy, of obliterating arteritis and of diabetic retina unsticking, only the use of this tincture can regulate the metabolism of lipids and hydrocarbonates.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT83901948T ATE22008T1 (de) | 1982-06-16 | 1983-05-26 | Arzneimittel zur behandlung der neoplasikkrankheit. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO107893 | 1982-06-16 | ||
| RO82107893A RO81783A3 (ro) | 1982-06-16 | 1982-06-16 | Medicament pentru tratamentul maladiei neoplazice |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0111529A1 true EP0111529A1 (de) | 1984-06-27 |
| EP0111529B1 EP0111529B1 (en) | 1986-09-10 |
Family
ID=20111710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP83901948A Expired EP0111529B1 (en) | 1982-06-16 | 1983-05-26 | Medicine for the treatment of the neoplazic disease |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0111529B1 (de) |
| CA (1) | CA1203167A (de) |
| DD (1) | DD210843A5 (de) |
| DE (1) | DE3366025D1 (de) |
| IL (1) | IL68896A0 (de) |
| IT (1) | IT1161934B (de) |
| RO (1) | RO81783A3 (de) |
| WO (1) | WO1984000005A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3015481B1 (fr) * | 2013-12-20 | 2016-08-12 | Etat Francais Represente Par Le Delegue General Pour L'armement | Utilisation de composes de diaminophenothiazinium en tant qu'agents de prevention, reduction ou suppression d'une radiotoxicite |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2244468A1 (en) * | 1973-07-31 | 1975-04-18 | Passwater Richard | Anticarcinogenic food supplements - contg antioxidants and S-contg amino acids |
-
1982
- 1982-06-16 RO RO82107893A patent/RO81783A3/ro unknown
-
1983
- 1983-05-26 DE DE8383901948T patent/DE3366025D1/de not_active Expired
- 1983-05-26 WO PCT/RO1983/000001 patent/WO1984000005A1/fr not_active Ceased
- 1983-05-26 EP EP83901948A patent/EP0111529B1/en not_active Expired
- 1983-06-06 IL IL68896A patent/IL68896A0/xx unknown
- 1983-06-14 DD DD83252009A patent/DD210843A5/de unknown
- 1983-06-14 IT IT21614/83A patent/IT1161934B/it active
- 1983-06-15 CA CA000430434A patent/CA1203167A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IL68896A0 (en) | 1983-10-31 |
| EP0111529B1 (en) | 1986-09-10 |
| DD210843A5 (de) | 1984-06-27 |
| WO1984000005A1 (fr) | 1984-01-05 |
| IT8321614A0 (it) | 1983-06-14 |
| RO81783B1 (ro) | 1984-03-08 |
| IT1161934B (it) | 1987-03-18 |
| CA1203167A (en) | 1986-04-15 |
| DE3366025D1 (en) | 1986-10-16 |
| RO81783A3 (ro) | 1984-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bonnemain | Helix and drugs: snails for western health care from antiquity to the present | |
| US3920816A (en) | Composition for treating respiratory diseases | |
| CN1211175A (zh) | 药物制剂以及一种人体的药物作用方法 | |
| US20050287230A1 (en) | Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof | |
| US5155096A (en) | Method for potentiation of a therapeutic agent | |
| EP0111529B1 (en) | Medicine for the treatment of the neoplazic disease | |
| HARRIS et al. | Coexistent systemic lupus erythematosus and porphyria | |
| WO1997027845A1 (en) | Antiglucocorticoid drug | |
| Rainsford | History and development of the salicylates | |
| RU2147239C1 (ru) | Общеукрепляющее неспецифическое иммуномодулирующее средство | |
| Melnyk et al. | Spontaneous remission of Zollinger-Ellison syndrome | |
| US4247540A (en) | Therapeutic agent | |
| CN1046089C (zh) | 外敷用抗甲状腺乳膏 | |
| CN118340758B (zh) | 香茶菜属四环二萜化合物在制备nlrp3炎症小体抑制剂中的应用 | |
| Dennison et al. | Fixed eruption due to penicillin allergy | |
| JPH04187640A (ja) | 経口・経皮免疫機能促進剤、動物用経口・経皮免疫機能促進剤 | |
| Neligan | Medicines, their use and mode of administration | |
| TWI707691B (zh) | 使大分子藥物經皮膚通透之組合物 | |
| RU2185843C2 (ru) | Способ лечения заболеваний печени и желчевыводящих путей | |
| RU2107503C1 (ru) | Средство для обезболивания | |
| DE2015877A1 (de) | Arzneimittel | |
| Peruchi | A substitute for quinine? Early medical-pharmaceutical studies on pereirine in nineteenth-century Brazil | |
| RU2048809C1 (ru) | Способ улучшения адаптации организма человека | |
| Southam et al. | False positive trichina precipitin reactions in neoplastic disease | |
| RU95109597A (ru) | Способ получения препарата "апсорин" для лечения псориаза и способ лечения псориаза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19840220 |
|
| AK | Designated contracting states |
Designated state(s): AT DE FR |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| PUAC | Information related to the publication of a b1 document modified or deleted |
Free format text: ORIGINAL CODE: 0009299EPPU |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT DE FR |
|
| REF | Corresponds to: |
Ref document number: 22008 Country of ref document: AT Date of ref document: 19860915 Kind code of ref document: T |
|
| DB1 | Publication of patent cancelled | ||
| 18W | Application withdrawn |
Withdrawal date: 19860717 |
|
| REF | Corresponds to: |
Ref document number: 3366025 Country of ref document: DE Date of ref document: 19861016 |
|
| EN | Fr: translation not filed | ||
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DANILA, MIHAI |